Discount sale is live
all report title image

DESONIDE MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2025 - 2032)

Desonide Market, By Formulation (Cream/Ointment, Foam, Lotion, and Gel), By Type (Generic and Brand), By Prescription Status (Prescription-only (Rx) and Over-the-Counter (OTC)), By Indication (Atopic dermatitis (Mild to Moderate), Seborrheic dermatitis, Contact dermatitis (allergic/irritant), and Others (Psoriasis)), By Distribution Channel (Hospital pharmacies, Retail pharmacies, and Online pharmacies), By End User (Hospitals, Specialty and dermatology clinics, Homecare Settings, and Others), By Age Group (Adult, Children, and Geriatric), By Geography (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa)

  • Published In : 18 Sep, 2025
  • Code : CMI8617
  • Pages :168
  • Formats :
      Excel and PDF
  • Industry : Pharmaceutical
  • 歴史的範囲: 2020 - 2024
  • 歴史的範囲: 2020 - 2024
Ingographics Image

The global desonide market is estimated to be valued at USD 162.5 Mn in 2025 and is expected to reach USD 254.2 Mn by 2032, exhibiting a compound annual growth rate (CAGR) of 6.6% from 2025 to 2032. The global desonide market represents a specialized segment within the dermatological therapeutics industry, centered around a low-potency topical corticosteroid widely prescribed for treating various inflammatory skin conditions. Desonide, classified as a Class VI corticosteroid, demonstrates exceptional safety profiles and efficacy in managing conditions such as atopic dermatitis, seborrheic dermatitis, contact dermatitis, and psoriasis, particularly in sensitive areas like the face and intertriginous regions.

This synthetic corticosteroid functions by reducing inflammation, itching, and redness through its anti-inflammatory, antipruritic, and vasoconstrictive properties, making it a preferred choice among dermatologists for pediatric and adult patients requiring gentle yet effective treatment. The market encompasses various formulations including creams, ointments, lotions, gels, and foam preparations, each designed to optimize drug delivery and patient compliance across diverse skin types and conditions. Growing awareness about skin health, increasing prevalence of dermatological disorders, rising healthcare expenditure, and expanding access to specialized dermatological treatments are driving significant growth in this market. The desonide market serves as a critical component of the broader topical corticosteroids market, addressing the substantial unmet medical need for safe, effective, and well-tolerated anti-inflammatory treatments in dermatology practice worldwide.

Market Dynamics

The global desonide market experiences robust growth driven by several key factors that collectively enhance its market potential and adoption rates across healthcare systems worldwide. Primary market drivers include the escalating prevalence of inflammatory skin conditions such as atopic dermatitis, contact dermatitis, and psoriasis, which affects millions globally and creates sustained demand for effective topical treatments. The increasing awareness among healthcare providers and patients regarding the superior safety profile of low-potency corticosteroids like desonide, particularly for sensitive skin areas and long-term use, significantly boosts market adoption. Growing pediatric dermatology applications drive substantial market expansion, as desonide's gentle formulation makes it suitable for children's delicate skin, addressing the rising incidence of childhood eczema and dermatitis.

However, market growth faces certain restraints including the availability of alternative treatment options such as topical calcineurin inhibitors, newer biologics, and advanced dermatological therapies that may limit desonide adoption in specific patient populations. Generic competition poses pricing pressure on branded desonide products, potentially affecting profit margins for pharmaceutical companies. Regulatory challenges related to topical corticosteroid approvals and safety monitoring requirements may slow new product launches and market entry strategies. Nevertheless, significant opportunities emerge from expanding healthcare infrastructure in developing markets, increasing healthcare spending on dermatological conditions, and growing demand for over-the-counter dermatological treatments. The development of novel formulations, combination therapies, and improved drug delivery systems presents substantial growth prospects. Rising medical tourism, telemedicine adoption for dermatological consultations, and increasing focus on quality-of-life improvements related to skin conditions create additional market opportunities for desonide manufacturers and distributors.

Key Features of the Study

  • This report provides in-depth analysis of the global desonide market, and provides market size (USD Million) and compound annual growth rate (CAGR%) for the forecast period (2025–2032), considering 2024 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global desonide market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study include GlaxoSmithKline plc, Galderma Laboratories, Mylan Pharmaceuticals (Viatris), Taro Pharmaceutical Industries Ltd., Glenmark Pharmaceuticals Ltd., Dr. Reddy’s Laboratories Ltd., Lupin Limited, Sun Pharmaceutical Industries Ltd., Zydus Lifesciences Ltd., Akorn Pharmaceuticals, Fougera Pharmaceuticals (Sandoz/Novartis), Perrigo Company plc, Teva Pharmaceuticals Industries Ltd., Alembic Pharmaceuticals Ltd., and Cadila Pharmaceuticals
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global desonide market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global desonide market

Market Segmentation

  • Formulation Insights (Revenue, USD Mn, 2020 - 2032)
    • Cream/Ointment
    • Foam
    • Lotion
    • Gel
  • Type Insights (Revenue, USD Mn, 2020 - 2032)
    • Generic
    • Brand
  • Prescription Status Insights (Revenue, USD Mn, 2020 - 2032)
    • Prescription-only (Rx)
    • Over-the-Counter (OTC)
  • Indication Insights (Revenue, USD Mn, 2020 - 2032)
    • Atopic dermatitis (Mild to Moderate)
    • Seborrheic dermatitis
    • Contact dermatitis (allergic/irritant)
    • Others (Psoriasis)
  • Distribution Channel Insights (Revenue, USD Mn, 2020 - 2032)
    • Hospital pharmacies
    • Retail pharmacies
    • Online pharmacies
  • End User Insights (Revenue, USD Mn, 2020 - 2032)
    • Hospitals
    • Specialty and dermatology clinics
    • Homecare Settings
    • Others
  • Age Group Insights (Revenue, USD Mn, 2020 - 2032)
    • Adult
    • Children
    • Geriatric
  • Regional Insights (Revenue, USD Mn, 2020 - 2032)
    • North America
      • U.S.
      • Canada
    • Latin America
      • Brazil
      • Argentina
      • Mexico
      • Rest of Latin America
    • Europe
      • Germany
      • U.K.
      • Spain
      • France
      • Italy
      • Russia
      • Rest of Europe
    • Asia Pacific
      • China
      • India
      • Japan
      • Australia
      • South Korea
      • ASEAN
      • Rest of Asia Pacific
    • Middle East
      • GCC Countries
      • Israel
      • Rest of Middle East
    • Africa
      • South Africa
      • North Africa
      • Central Africa
  • Key Players Insights
    • Pfizer Inc.
    • GlaxoSmithKline plc
    • Galderma Laboratories
    • Mylan Pharmaceuticals (Viatris)
    • Taro Pharmaceutical Industries Ltd.
    • Glenmark Pharmaceuticals Ltd.
    • Reddy Laboratories Ltd.
    • Lupin Limited
    • Sun Pharmaceutical Industries Ltd.
    • Zydus Lifesciences Ltd.
    • Akorn Pharmaceuticals
    • Fougera Pharmaceuticals (Sandoz/Novartis)
    • Perrigo Company plc
    • Teva Pharmaceuticals Industries Ltd.
    • Alembic Pharmaceuticals Ltd.
    • Cadila Pharmaceuticals

Table of Contents

  1. Research Objectives and Assumptions
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Global Desonide Market, By Formulation
      • Global Desonide Market, By Type
      • Global Desonide Market, By Prescription Status
      • Global Desonide Market, By Indication
      • Global Desonide Market, By Distribution Channel
      • Global Desonide Market, By End User
      • Global Desonide Market, By Age Group
      • Global Desonide Market, By Region
  3. Market dynamics, regulations, and trends analysis
    • Market Dynamics
    • Driver
    • Restraint
    • Opportunity
    • Impact Analysis
    • Key Developments
    • Regulatory Scenario
    • Product Launches/Approvals
    • PEST Analysis
    • PORTER’s Analysis
    • Merger and Acquisition Scenario
    • Industry Trends
  4. Global Desonide Market, By Formulation, 2020-2032, (USD Mn)
    • Introduction
      • Market Share Analysis, 2025 and 2032 (%)
      • Y-o-Y Growth Analysis, 2021 - 2032
      • Segment Trends
    • Cream/Ointment
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
    • Foam
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
    • Lotion
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
    • Gel
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
  5. Global Desonide Market, By Type, 2020-2032, (USD Mn)
    • Introduction
      • Market Share Analysis, 2025 and 2032 (%)
      • Y-o-Y Growth Analysis, 2021 - 2032
      • Segment Trends
    • Generic
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
    • Brand
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
  6. Global Desonide Market, By Prescription Status, 2020-2032, (USD Mn)
    • Introduction
      • Market Share Analysis, 2025 and 2032 (%)
      • Y-o-Y Growth Analysis, 2021 - 2032
      • Segment Trends
    • Prescription-only (Rx)
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
    • Over-the-Counter (OTC)
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
  7. Global Desonide Market, By Indication, 2020-2032, (USD Mn)
    • Introduction
      • Market Share Analysis, 2025 and 2032 (%)
      • Y-o-Y Growth Analysis, 2021 - 2032
      • Segment Trends
    • Atopic dermatitis (Mild to Moderate)
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
    • Seborrheic dermatitis
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
    • Contact dermatitis (allergic/irritant)
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
    • Others (Psoriasis)
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
  8. Global Desonide Market, By Distribution Channel, 2020-2032, (USD Mn)
    • Introduction
      • Market Share Analysis, 2025 and 2032 (%)
      • Y-o-Y Growth Analysis, 2021 - 2032
      • Segment Trends
    • Hospital pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
    • Retail pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
    • Online pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
  9. Global Desonide Market, By End User, 2020-2032, (USD Mn)
    • Introduction
      • Market Share Analysis, 2025 and 2032 (%)
      • Y-o-Y Growth Analysis, 2021 - 2032
      • Segment Trends
    • Hospitals
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
    • Specialty and dermatology clinics
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
    • Homecare Settings
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
    • Others
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
  10. Global Desonide Market, By Age Group, 2020-2032, (USD Mn)
    • Introduction
      • Market Share Analysis, 2025 and 2032 (%)
      • Y-o-Y Growth Analysis, 2021 - 2032
      • Segment Trends
    • Adult
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
    • Children
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
    • Geriatric
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
  11. Global Desonide Market, By Region, 2020 - 2032, Value (USD Mn)
    • Introduction
      • Market Share (%) Analysis, 2025, 2028 & 2032, Value (USD Mn)
      • Market Y-o-Y Growth Analysis (%), 2021 - 2032, Value (USD Mn)
      • Regional Trends
    • North America
      • Introduction
      • Market Size and Forecast, By Formulation, 2020 - 2032, Value (USD Mn)
      • Market Size and Forecast, By Type, 2020 - 2032, Value (USD Mn)
      • Market Size and Forecast, By Prescription Status, 2020 - 2032, Value (USD Mn)
      • Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Mn)
      • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Mn)
      • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Mn)
      • Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Mn)
      • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Mn)
        • U.S.
        • Canada
    • Latin America
      • Introduction
      • Market Size and Forecast, By Formulation, 2020 - 2032, Value (USD Mn)
      • Market Size and Forecast, By Type, 2020 - 2032, Value (USD Mn)
      • Market Size and Forecast, By Prescription Status, 2020 - 2032, Value (USD Mn)
      • Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Mn)
      • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Mn)
      • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Mn)
      • Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Mn)
      • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Mn)
        • Brazil
        • Argentina
        • Mexico
        • Rest of Latin America
    • Europe
      • Introduction
      • Market Size and Forecast, By Formulation, 2020 - 2032, Value (USD Mn)
      • Market Size and Forecast, By Type, 2020 - 2032, Value (USD Mn)
      • Market Size and Forecast, By Prescription Status, 2020 - 2032, Value (USD Mn)
      • Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Mn)
      • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Mn)
      • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Mn)
      • Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Mn)
      • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Mn)
        • Germany
        • U.K.
        • Spain
        • France
        • Italy
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Introduction
      • Market Size and Forecast, By Formulation, 2020 - 2032, Value (USD Mn)
      • Market Size and Forecast, By Type, 2020 - 2032, Value (USD Mn)
      • Market Size and Forecast, By Prescription Status, 2020 - 2032, Value (USD Mn)
      • Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Mn)
      • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Mn)
      • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Mn)
      • Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Mn)
      • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Mn)
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • Introduction
      • Market Size and Forecast, By Formulation, 2020 - 2032, Value (USD Mn)
      • Market Size and Forecast, By Type, 2020 - 2032, Value (USD Mn)
      • Market Size and Forecast, By Prescription Status, 2020 - 2032, Value (USD Mn)
      • Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Mn)
      • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Mn)
      • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Mn)
      • Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Mn)
      • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Mn)
        • GCC Countries
        • Israel
        • Rest of Middle East
    • Africa
      • Introduction
      • Market Size and Forecast, By Formulation, 2020 - 2032, Value (USD Mn)
      • Market Size and Forecast, By Type, 2020 - 2032, Value (USD Mn)
      • Market Size and Forecast, By Prescription Status, 2020 - 2032, Value (USD Mn)
      • Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Mn)
      • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Mn)
      • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Mn)
      • Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Mn)
      • Market Size and Forecast, By Country/Region, 2020 - 2032, Value (USD Mn)
        • South Africa
        • North Africa
        • Central Africa
  12. Competitive Landscape
    • Pfizer Inc.
      • Company Highlights
      • Product Portfolio
      • Key Developments
      • Financial Performance
      • Strategies
    • GlaxoSmithKline plc
      • Company Highlights
      • Product Portfolio
      • Key Developments
      • Financial Performance
      • Strategies
    • Galderma Laboratories
      • Company Highlights
      • Product Portfolio
      • Key Developments
      • Financial Performance
      • Strategies
    • Mylan Pharmaceuticals (Viatris)
      • Company Highlights
      • Product Portfolio
      • Key Developments
      • Financial Performance
      • Strategies
    • Taro Pharmaceutical Industries Ltd.
      • Company Highlights
      • Product Portfolio
      • Key Developments
      • Financial Performance
      • Strategies
    • Glenmark Pharmaceuticals Ltd.
      • Company Highlights
      • Product Portfolio
      • Key Developments
      • Financial Performance
      • Strategies
    • Reddy Laboratories Ltd.
      • Company Highlights
      • Product Portfolio
      • Key Developments
      • Financial Performance
      • Strategies
    • Lupin Limited
      • Company Highlights
      • Product Portfolio
      • Key Developments
      • Financial Performance
      • Strategies
    • Sun Pharmaceutical Industries Ltd.
      • Company Highlights
      • Product Portfolio
      • Key Developments
      • Financial Performance
      • Strategies
    • Zydus Lifesciences Ltd.
      • Company Highlights
      • Product Portfolio
      • Key Developments
      • Financial Performance
      • Strategies
    • Akorn Pharmaceuticals
      • Company Highlights
      • Product Portfolio
      • Key Developments
      • Financial Performance
      • Strategies
    • Fougera Pharmaceuticals (Sandoz/Novartis)
      • Company Highlights
      • Product Portfolio
      • Key Developments
      • Financial Performance
      • Strategies
    • Perrigo Company plc
      • Company Highlights
      • Product Portfolio
      • Key Developments
      • Financial Performance
      • Strategies
    • Teva Pharmaceuticals Industries Ltd.
      • Company Highlights
      • Product Portfolio
      • Key Developments
      • Financial Performance
      • Strategies
    • Alembic Pharmaceuticals Ltd.
      • Company Highlights
      • Product Portfolio
      • Key Developments
      • Financial Performance
      • Strategies
    • Cadila Pharmaceuticals
      • Company Highlights
      • Product Portfolio
      • Key Developments
      • Financial Performance
      • Strategies
  13. Analyst Recommendations
    • Wheel of Fortune
    • Analyst View
    • Coherent Opportunity Map
  14. References and Research Methodology
    • References
    • Research Methodology
    • About Us

*Browse 32 market data tables and 28 figures on ‘Desonide Market' - Global forecast to 2032

  • Need a Custom Report?

    We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports

    Customize Now
Logo

Credibility and Certifications

ESOMAR
DUNS Registered

860519526

Clutch
Credibility and Certification
Credibility and Certification

9001:2015

Credibility and Certification

27001:2022

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo
© 2025 Coherent Market Insights Pvt Ltd. All Rights Reserved.